210 results on '"Yukihiro Kondo"'
Search Results
2. Vesicocutaneous fistula due to vesical diverticulitis with stones: A case report and literature review
- Author
-
Jun Akatsuka, Kyota Suzuki, Shunsuke Ikuma, Masato Yanagi, Yuki Endo, Hayato Takeda, Yuka Toyama, Teruyuki Dohi, Go Kimura, and Yukihiro Kondo
- Subjects
Urology - Published
- 2022
- Full Text
- View/download PDF
3. Efficacy and Safety of Transurethral Enucleation with Bipolar Energy for Treatment of Benign Prostatic Hyperplasia: Does Prostate Volume Matter?
- Author
-
Yuki, Endo, Hiroyuki, Shimizu, Jun, Akatsuka, Shigehito, Minaguchi, Hiroya, Hasegawa, Yuka, Toyama, Yasutomo, Suzuki, Tsutomu, Hamasaki, Mamoru, Oki, Jun, Hasegawa, and Yukihiro, Kondo
- Subjects
Male ,Treatment Outcome ,Prostate ,Prostatic Hyperplasia ,Quality of Life ,Transurethral Resection of Prostate ,Humans ,General Medicine ,Prostate-Specific Antigen ,Retrospective Studies - Abstract
We evaluated the association of prostate volume (PV) with the efficacy and safety of transurethral enucleation with bipolar energy (TUEB) for treatment of benign prostatic hyperplasia (BPH).We retrospectively evaluated data from 180 patients with symptomatic BPH who underwent TUEB between 2008 and 2015. Efficacy was assessed by perioperative changes in international prostate symptom score (IPSS), Quality of Life Score (QOLS), maximum flow rate on uroflowmetry (Qmax), and serum prostate-specific antigen level (PSA), which were recorded at 3 months postoperatively. Safety was assessed by perioperative incidence of adverse events (AEs). AEs were recorded up to 2 years after surgery. Patients were divided into two groups based on PV as the standard group (SG; PV80 mL) and large group (LG; PV ≥ 80 mL).A total of 132 (73%) patients were grouped as the SG, and 48 (27%) were grouped as the LG. No significant differences between the groups were observed in the preoperative variables age, IPSS, and QOLS. However, the LG had a significantly larger PV and higher serum PSA levels. Analysis of surgical outcomes revealed that postoperative changes in IPSS, QOLS, Qmax, serum PSA, serum sodium, and hemoglobin levels did not differ significantly between groups. However, LG had a significantly longer operative time and heavier specimen weight. The rates of early complications, including hyponatremia and blood transfusion, and late complications after surgery did not differ between the groups.The present findings suggest that TUEB is safe and effective for treatment of BPH, regardless of PV.
- Published
- 2022
- Full Text
- View/download PDF
4. A case of complete resection of prostate stromal sarcoma after neoadjuvant chemotherapy
- Author
-
Naoto Hodotsuka, Yasutomo Suzuki, Kyota Suzuki, Yuichiro Honda, Shuma Endo, Eigo Kuribayashi, Kotaro Obayashi, Tadaaki Minowa, Tsutomu Hatori, and Yukihiro Kondo
- Subjects
Urology - Published
- 2023
- Full Text
- View/download PDF
5. Determining the clinicopathological significance of the VI-RADS true-positive group: A retrospective study
- Author
-
Shunsuke Ikuma, Jun Akatsuka, Hayato Takeda, Yuki Endo, Tsutomu Hamasaki, Go Kimura, and Yukihiro Kondo
- Abstract
Background The Vesical Imaging Reporting and Data System (VI-RADS) is widely used as a diagnostic method for predicting muscle-invasive bladder cancer (MIBC). This study aimed to determine the clinicopathological significance of the VI-RADS true-positive (TP) group.Methods We performed 333 transurethral resections of bladder tumors (TURBT) at our hospital between January 2019 and April 2021, and included 125 patients who underwent preoperative Magnetic resonance imaging (MRI) into this study. The patients were pathologically diagnosed with urothelial carcinoma (UC). We first compared the results of patients with VI-RADS scores of 3 and 4 to determine the cut-off values for MIBC; thereafter, the 125 patients were divided into TP, false-positive (FP), true-negative (TN), and false-negative (FN) groups using VI-RADS. The clinicopathological significance of the TP group was examined by retrospectively comparing the characteristics of each group.Results A total of 125 cases were examined, out of which 29 were pathologically diagnosed with MIBC. Of the 29 MIBC cases, 4 (13.8%) had a VI-RADS score of ≤ 3 and 25 (86.2%) had a VI-RADS score of ≥ 4. Of the 96 Non-muscle-invasive bladder cancer (NMIBC) cases, 83 (86.5%) had a VI-RADS score of ≤ 3 and 13 (13.5%) had a VI-RADS score of ≥ 4. The diagnostic performance of the VI-RADS with a cutoff value of 4 was 87.1% for sensitivity, 86.5% for specificity, and an area under the curve (AUC) of 0.87. In contrast, for a cutoff value of 3, the sensitivity was 90.3%, specificity was 61.5%, and AUC was 0.76. In this study, a VI-RADS score of ≥ 4 could predict MIBC. In the TP group, all 25 patients had high-grade tumors. The TP group had significantly more high-grade bladder cancers than the other groups (TP vs. TN, p = 0.001; TP vs. FP, p = 0.009; and TP vs. FN, p = 0.0278). In addition, the TP group had more tumor necrosis (TP vs. TN, p = 0.001; TP vs. FP, p = 0.0045) and more UC variant cases (TP vs. TN, p = 0.0012; TP vs. FP, p = 0.0217) than the TN and FP groups.Conclusion This study suggests that VI-RADS has a high diagnostic performance in predicting MIBC, and that VI-RADS could diagnose high-grade tumors, necrosis, and UC variants.
- Published
- 2023
- Full Text
- View/download PDF
6. Outcome of Modified Laparoscopic Sacrocolpopexy and Its Effect on Voiding Dysfunction
- Author
-
Yasutomo Suzuki, Satoko Nakayama, Masao Ichikawa, Yuka Toyama, Shigeo Akira, Yuki Endo, and Yukihiro Kondo
- Subjects
Male ,medicine.medical_specialty ,Urinary Incontinence, Stress ,media_common.quotation_subject ,Urinary system ,Urology ,Urinary incontinence ,urologic and male genital diseases ,Urination ,Pelvic Organ Prolapse ,Cystography ,medicine ,Humans ,Retrospective Studies ,media_common ,medicine.diagnostic_test ,Urinary retention ,business.industry ,General Medicine ,Perioperative ,medicine.disease ,Urodynamics ,Overactive bladder ,Female ,Laparoscopy ,International Prostate Symptom Score ,sense organs ,medicine.symptom ,business - Abstract
Background Laparoscopic sacrocolpopexy (LSC) is an increasingly popular treatment for pelvic organ prolapse (POP) because of its low recurrence rate and safety. Although LSC may improve the voiding function, it may also lead to de novo stress urinary incontinence. The detailed impact of LSC on voiding function and its mechanism remain unclear. Therefore, in this study, we evaluated the impact of LSC on voiding function prospectively by performing a pre- and post-operative urodynamic study in patients with stage 3 or greater POP. Methods Urinary status was evaluated before and 3 months after LSC. Pre- and post-operative evaluations included medical history, clinical examination, urodynamic studies, chain cystography, and residual urine volume measurement. Urinary symptoms were assessed using the International Prostate Symptom Score (IPSS) and the Overactive Bladder Symptom Score (OABSS). Results The non-recurrence rate at 3 months was 82.3%. All recurrences involved bladder prolapse. Apart from the fact that there was no significant change in the OABSS, the improvement in IPSS suggests that subjective voiding symptoms have improved. Although the maximum urinary flow rate did not change significantly, the bladder volume at first sensation increased, urinary storage function improved, and residual urine volume decreased. There were no perioperative complications, and none of the patients complained of post-operative difficulty in urination or urinary retention. The retrovesical angle significantly decreased. Conclusions The modified LSC in women with POP provides good functional outcomes in terms of IPSS, post void residual volume (PVR), and urinary storage function.
- Published
- 2022
- Full Text
- View/download PDF
7. Perirenal fat stranding as a predictor of disease progression after radical nephroureterectomy for renal pelvic urothelial carcinoma: A retrospective study
- Author
-
Masato Yanagi, Mika Terasaki, Tomonari Kiriyama, Yasuhiro Terasaki, Jun Akatsuka, Yuki Endo, Taiji Nishimura, Akira Shimizu, and Yukihiro Kondo
- Abstract
Background To investigate the impact of Perirenal fat stranding (PRFS) on progression after radical nephroureterectomy (RNU) for pelvic urothelial carcinoma (RPUC) without hydronephrosis and to reveal the pathological findings of PRFS. Methods Clinicopathological data, including computed tomography (CT) findings of the ipsilateral and contralateral PRFS, were collected from the medical records of 56 patients treated with RNU for renal RPUC without hydronephrosis between 2011 and 2021 at our institution. Ipsilateral PRFS on CT was classified as either low or high PRFS. The impact of PRFS on progression-free survival (PFS) after RNU was analyzed using the Kaplan-Meier method and log-rank test. In addition, specimens including sufficient perirenal fat from patients with low and with high PRFS were pathologically analyzed. Results Of the 56 patients, 31(55.4%) and 25 (44.6%) patients were classified as having low and high PRFS, respectively. Within a median follow-up of 40.6 months postoperatively, 11 (19.6%) patients showed disease progression. The Kaplan-Meier method and log-rank test revealed that patients with ipsilateral high PRFS had significantly lower PFS rates than those with ipsilateral low PRFS (3-year PFS 69.8% vs 93.3%; p=0.0393). Pathological analysis revealed that ipsilateral high PRFS specimens (n=3 patients) contained more fibrous strictures in perirenal fat than ipsilateral low PRFS specimens (n=3 patients). Conclusions PRFS of RPUC without hydronephrosis consists of collagenous fibers. The presence of ipsilateral high PRFS is a risk factor for progression after RNU for RPUC patients without hydronephrosis. Strict follow-up after surgery is thus recommended for these patients.
- Published
- 2023
- Full Text
- View/download PDF
8. Rhabdomyolysis after Retroperitoneal Laparoscopic Radical Nephrectomy in the Lateral Decubitus Position
- Author
-
Masato Yanagi, Tsutomu Hamasaki, Kojiro Morita, Hayato Takeda, Jun Akatsuka, Yuki Endo, Tatsuro Hayashi, and Yukihiro Kondo
- Subjects
Adult ,Humans ,Female ,Laparoscopy ,General Medicine ,Obesity ,Carcinoma, Renal Cell ,Nephrectomy ,Kidney Neoplasms ,Rhabdomyolysis - Abstract
Postoperative rhabdomyolysis is a rare but potentially fatal surgical complication. We experienced a case of rhabdomyolysis after laparoscopic radical nephrectomy (LRN). Right renal carcinoma was diagnosed in a 31-year-old woman with a body mass index of 28.5 kg/m
- Published
- 2022
9. Effect of Robot-assisted Surgery on Anesthetic and Perioperative Management for Minimally Invasive Radical Prostatectomy under Combined General and Epidural Anesthesia
- Author
-
Kishikawa, Hiroaki, Suzuki, Norihito, Suzuki, Yasutomo, Hamasaki, Tsutomu, Kondo, Yukihiro, Sakamoto, Atsuhiro, Hiroaki, Kishikawa, Norihito, Suzuki, Yasutomo, Suzuki, Tsutomu, Hamasaki, Yukihiro, Kondo, and Atsuhiro, Sakamoto
- Subjects
Adult ,Anesthesia, Epidural ,Male ,Laparoscopic surgery ,medicine.medical_specialty ,Laparoscopic radical prostatectomy ,medicine.medical_treatment ,Anesthesia, General ,Perioperative Care ,Robotic Surgical Procedures ,medicine ,Humans ,Minimally Invasive Surgical Procedures ,Colloids ,Aged ,Anesthetics ,Retrospective Studies ,Prostatectomy ,Ropivacaine ,business.industry ,Medical record ,Retrospective cohort study ,Crystalloid Solutions ,General Medicine ,Length of Stay ,Middle Aged ,Drug Utilization ,Surgery ,Treatment Outcome ,Anesthesia ,Anesthetic ,medicine.symptom ,business ,Postoperative nausea and vomiting ,medicine.drug - Abstract
Background Robot-assisted surgery and pure laparoscopic surgery are available for minimally invasive radical prostatectomy (MIRP). The differences in anesthetic management between the two MIRPs under combined general and epidural anesthesia (CGEA) remain unknown. This study therefore aimed to determine the effects of robot-assisted surgery on anesthetic and perioperative management for MIRP under CGEA. Methods A retrospective observational study was performed by obtaining data from the patients' electronic medical records. Demographic data, intraoperative parameters, postoperative complications, and hospital stays after the MIRPs were compared between patients who underwent robot-assisted laparoscopic radical prostatectomy (RALP) and those with pure laparoscopic radical prostatectomy (LRP). Results There were no differences in the patients' background data between the 102 who underwent RALP and 112 who underwent LRP. Anesthesia and surgical times were shorter in the RALP group than in the LRP group. Consumption of anesthetics, including intravenous opioids, and epidural ropivacaine, was less in the RALP group. Although the estimated blood loss and volume of colloid infusion were lower in the RALP group, the volume of crystalloid infusion was larger. Intraoperative allogeneic transfusion was not required in either group. There were no differences in incidents of postoperative cardiopulmonary complications or postoperative nausea and vomiting (PONV) in either MIRP group. Hospital stays after the procedure were shorter in the RALP group. Conclusions Robot-assisted surgery required varied consumption of anesthetics and infusion management during MIRP under GCEA. It also shortened the postoperative hospital stay without increasing the rates of postoperative complications.
- Published
- 2021
- Full Text
- View/download PDF
10. Penile Strangulation in an Elderly Patient
- Author
-
Tatsuro Hayashi, Takayuki Ueda, Jun Akatsuka, Mikio Shibasaki, Yuki Endo, Yukihiro Kondo, Kotaro Obayashi, Teruyuki Dohi, Hiroya Hasegawa, and Hikaru Mikami
- Subjects
medicine.medical_specialty ,business.industry ,Medicine ,business ,Elderly patient ,Surgery - Published
- 2021
- Full Text
- View/download PDF
11. Compartment Syndrome after Prostatectomy
- Author
-
Yuki Endo, Jun Akatsuka, Kosuke Kuwahara, Suisen Takasaki, Hayato Takeda, Masato Yanagi, Yuka Toyama, Hikaru Mikami, Tsutomu Hamasaki, and Yukihiro Kondo
- Subjects
Male ,Prostatectomy ,Leg ,adverse event ,Prostatic Neoplasms ,Cellulitis ,General Medicine ,Robotics ,Compartment Syndromes ,General Biochemistry, Genetics and Molecular Biology ,Postoperative Complications ,well leg compartment syndrome ,Eosinophilia ,Robot-assisted Laparoscopic radical prostatectomy ,Humans ,Laparoscopy ,Aged - Abstract
Robot-assisted laparoscopic prostatectomy (RALP) for prostate cancer was introduced in 2000 and rapidly gained popularity. The Da Vinci Surgical System? can ensure improved local control of cancer and fewer perioperative complications. However, RALP is performed in the steep-Trendelenburg position (a combination of lithotomy and head-down tilt position/Lloyd-Davies position) to obtain a good surgical view, and as a result, well leg compartment syndrome (WLCS) can become a serious complication of RALP. Here, we report a case of WLCS after RALP. A 75-year-old man underwent surgery for prostate cancer and immediately complained of pain and numbness after surgery. The pressure of the four leg compartments increased. Ultimately, we diagnosed the patient with WLCS in his right leg, and an emergency fasciotomy was performed. He completely recovered with no permanent disability and was discharged one month after rehabilitation. Although WLCS after RALP is a rare and severe complication, the patient recovered completely with early diagnosis and intervention. Measuring the compartment pressure is useful when the patient is drowsy immediately after recovery from anesthesia. Preventing WLCS requires identifying this condition as a potential complication of RALP and all urologic surgeries performed in the lithotomy position. J. Med. Invest. 69 : 145-147, February, 2022.
- Published
- 2022
12. Efficacy and Safety of Axitinib Therapy After Nivolumab for Patients With Metastatic Renal Cell Cancer
- Author
-
Shotaro Yasuoka, Takeshi Yuasa, Junji Yonese, Ryo Fujiwara, Yukihiro Kondo, Yoshinobu Komai, Shinya Yamamoto, and Noboru Numao
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Axitinib ,Drug-Related Side Effects and Adverse Reactions ,Immune checkpoint inhibitors ,medicine.medical_treatment ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,In patient ,Metastatic renal cell cancer ,Adverse effect ,Carcinoma, Renal Cell ,Aged ,Chemotherapy ,business.industry ,Medical record ,General Medicine ,Middle Aged ,Nivolumab ,Female ,business ,medicine.drug - Abstract
Background/aim Tyrosine kinase inhibitors (TKI) and immune-checkpoint inhibitors (ICI) are treatment options for metastatic renal cell cancer (mRCC). However, the treatment options after nivolumab are unclear. Patients and methods The medical records of 57 consecutive Japanese mRCC patients who underwent treatment with axitinib were reviewed. Among those, 17 patients received axitinib treatment after nivolumab and 40 patients received axitinib treatment after other chemotherapy regimens except nivolumab. Results Of the 57 patients with mRCC, only 17 underwent axitinib therapy after nivolumab. Among these 17 patients, the objective response rate (ORR) and median tumor shrinkage rate were 56.3% and -30%, respectively. They were significantly better in patients who underwent axitinib therapy after nivolumab than after other therapies (p=0.026 and p=0.012, respectively). However, all 17 patients experienced some adverse events and nine patients (52.9%) required a dose reduction or axitinib treatment interruption. Conclusion Axitinib therapy after the immune checkpoint inhibitor nivolumab showed good efficacy with a moderate risk of adverse events. Careful management by skilled professionals may be required.
- Published
- 2020
- Full Text
- View/download PDF
13. Differential Diagnosis and Prognosis of Small Renal Masses: Association with Collateral Vessels Detected Using Contrast-Enhanced Computed Tomography
- Author
-
Masato Yanagi, Tomonari Kiriyama, Jun Akatsuka, Yuki Endo, Hayato Takeda, Akifumi Katsu, Yuichiro Honda, Kyota Suzuki, Yoshihiro Nishikawa, Shunsuke Ikuma, Hikaru Mikami, Yuka Toyama, Go Kimura, and Yukihiro Kondo
- Subjects
Cancer Research ,Contrast Media ,Prognosis ,urologic and male genital diseases ,Sensitivity and Specificity ,Kidney Neoplasms ,female genital diseases and pregnancy complications ,Diagnosis, Differential ,Oncology ,Genetics ,Humans ,Carcinoma, Small Cell ,Tomography, X-Ray Computed ,Carcinoma, Renal Cell ,Retrospective Studies - Abstract
Background Active surveillance (AS) is one of the treatment methods for patients with small renal masses (SRMs; Methods A total of 130 consecutive patients with pathologically confirmed non-metastatic SRMs (fat-poor angiomyolipomas [fpAMLs; n = 7] and RCCs [n = 123]) were retrospectively enrolled. Between 2011 and 2019, SRM diagnoses in these patients were confirmed after biopsy or surgical resection. All RCCs were surgically resected. Regardless of diameter, a collateral vessel (CV) was defined as any blood vessel connecting the tumor from around the kidney using CECT. First, we analyzed the role of CV-detection in differentiating between fpAML and RCC. Then, we evaluated the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of RCC diagnosis based on CV-detection using CECT. We also assessed the prognostic value of CV-detection using the Fisher exact test, and Kaplan-Meier method and the log-rank test. Results The sensitivity, specificity, PPV, NPV, and accuracy of CV-detection for the diagnosis of small RCCs was 48.5, 45.5, 100, 100, and 9.5% respectively. Five of 123 (4.1%) patients with RCC experienced recurrence. CV-detection using CECT was the only significant factor associated with recurrence (p = 0.0177). Recurrence-free survival (RFS) was significantly lower in patients with CV compared with in those without CV (5-year RFS 92.4% versus 100%, respectively; p = 0.005). In addition, critical review of the CT images revealed the CVs to be continuous with the venous vessels around the kidney. Conclusions The detection of CVs using CECT is useful for differentiating between small fpAMLs and RCCs. CV-detection may also be applied as a predictive parameter for small RCCs prone to recurrence after surgical resection. Moreover, AS could be suitable for small RCCs without CVs.
- Published
- 2022
- Full Text
- View/download PDF
14. Delivery of prostate cancer-associated non-coding RNAs within the bone marrow milieu
- Author
-
Toshihiro Takizawa, Syunya Noguchi, Satoshi Soeta, Hikaru Mikami, and Yukihiro Kondo
- Subjects
Reproductive Medicine ,Immunology ,Obstetrics and Gynecology ,Immunology and Allergy - Published
- 2023
- Full Text
- View/download PDF
15. Early switching to pembrolizumab (Pe) during first-line platinum-based chemotherapy (PCT) in patients (pts) with metastatic urothelial carcinoma (mUC)
- Author
-
Yuki Endo, Go Kimura, Jun Akatsuka, Hayato Takeda, Masato Yanagi, Hikaru Mikami, Hiroya Hasegawa, Mami Taniuchi, Akifumi Katsu, Ryota Funato, Yuka Toyama, and Yukihiro Kondo
- Subjects
Cancer Research ,Oncology - Abstract
452 Background: With the results of the Javelin bladder 100 trial, PCT followed by ICI has become the standard of care for pts with mUC. While more than half of the pts have progressive disease (PD) by the 4th cycle of PCT, in general, most these pts will receive ICI after 4th cycle of PCT. However, for pts who have PD before 4 cycles, additional PCT will not only be effective, but will also cause side effects and worsen immune environment. However, the outcome of early switching to ICI during 1st-line PCT has not been reported. Here, we investigated whether early switching to Pe may improve prognosis. We also examined the usefulness of serum CYFRA (sCY) as a prognostic marker of 2nd-line Pe in this study. Methods: Seventy pts with mUC received PCT followed by Pe from February 2018 to July 2022 at our institution. Among them 56 pts who had received PCT 3 cycles or less because of PD or unacceptable side effects were included in this study. During PCT, computed tomography (CT) was performed at the end of each cycle and PCT was continued until PD. If PD on CT was confirmed, 2nd-line Pe was initiated. Performance status, metastasis site, neutrophil-lymphocyte ratio, hemoglobin, and serum alkaline phosphatase, C-reactive protein, total protein, albumin, corrected calcium (Ca) and sCY before Pe were examined as possible prognostic factors for overall survival (OS). OS was analyzed by Kaplan-Meier curves and log-rank test. Multivariate analysis on prognostic factors was carried out using the Cox hazards model. Results: Median age was 73 (31-86). Twenty-seven pts (49%) received gemcitabine-cisplatin and 29 (51%) received gemcitabine-carboplatin for PCT. Twelve pts (21%) received 1 cycle of PCT, 2 cycles in 26 (46%) and 3 cycles in 18 (32%). During the median follow-up period of 14.6 (6.2-44.6) months (M), 30 pts (53.5%) had died. The median OS was 15.5M and the 1-year OS rate was 60%. The median PFS was 10.2M and the 1-year PFS rate was 46%. Objective response rate was 25% and 18 pts showed stable disease (32%) and 24 pts (43%) showed PD. On univariate analysis, sCY (p=0.001) and Ca (p=0.003) were the significant factors for OS. On multivariate analysis, sCY (HR 3.2, 95%CI [1.33-7.82], p=0.009) and Ca (HR2.3, (95%CI [1.02-5.22], p=0.046) were the significant factors for OS. Conclusions: Early switching to Pe during 1st-line PCT resulted in PFS of 10.2M and OS of 15.5M, which were longer than those of the KEYNOTE-045 trial (PFS 2M, OS 10M). Early introduction of Pe may be effective in the pts with mUC who are resistant to chemotherapy. sCY and Ca were suggested to be the useful prognostic factors for OS.
- Published
- 2023
- Full Text
- View/download PDF
16. Association of serum lactate dehydrogenase (LDH) isozyme with prognosis of patients with metastatic clear cell renal cell carcinoma (mCRCC)
- Author
-
Hayato Takeda, Go Kimura, Jun Akatsuka, Yuki Endo, Masato Yanagi, Hikaru Mikami, Hiroya Hasegawa, Akifumi Katsu, Ryota Funato, Mami Taniuchi, Yuka Toyama, and Yukihiro Kondo
- Subjects
Cancer Research ,Oncology - Abstract
709 Background: LDH isozyme is a tetramer of two subunits, H chain and M chain, and is present in all living tissue. Five types of molecular forms characterize the LDH pattern, and tumor tissues relatively consist LDH-4 and LDH-5, composed with a high ratio of the M chain, compared to normal tissues. This study analyzed the association between LDH isozyme and prognosis of mCRCC after nephrectomy. Methods: Clinical records of mCRCC patients those who were initially diagnosed M0 disease at Nippon Medical School between 2012 and 2016 were retrospectively reviewed. LDH isozyme values before operation and at time of metastasis were checked. Isozyme patterns were classified into 6 types, LDH 1-5 dominant and common type, according to the most composed molecular form. Results: Out of 38 patients, 33 patients (87%) were male, 5 patients (13%) were female. Median age was 65 years old (36-87). pT1 was seen in 3 cases, pT2 in 4, pT3 in 27, and pT4 in 4. Pathological grade 2 were 9 cases, G3 in 21, and G4 in 8. As for the IMDC risk, favourable was 2 cases (5%), intermediate in 26 (68%) and poor in 10 (26%). Median LDH was 163 IU/L (113-317), and isozyme dominant pattern were as follows: LDH-2 in 9 cases (24%), LDH-3 in 6 (16%), LDH-4 in 4, LDH-5 in 11. 8 cases were common type, and no cases showed LDH-1 dominant. Median time from surgery to recurrence was 10 months (1-104), median follow-up period after recurrence was 18 months (4-72). 16 deaths occurred. No significant correlation was seen between pre-operative LDH isozyme pattern and pathological grade or pT stage. Pre-operative LDH isozyme did not correlate with the time to recurrence (p=0.7420). The median OS for LDH-4 dominant at the time of metastasis was 10.9 months, significantly shorter than other isozyme types (P=0.0134). Conclusions: LDH-4 dominant isozyme pattern at the time of recurrence has a short OS, proposing as a prognostic predictor in mRCC.
- Published
- 2023
- Full Text
- View/download PDF
17. Risk factor analysis of intravesical recurrence after retroperitoneoscopic nephroureterectomy for upper tract urothelial carcinoma
- Author
-
Yukihiro Kondo, Hayato Takeda, Masato Yanagi, JunJun Akatsuka, Yuki Endo, and Tsutomu Hamasaki
- Subjects
Adult ,Male ,medicine.medical_specialty ,Urology ,Nephroureterectomy ,Risk Assessment ,symbols.namesake ,Risk Factors ,medicine ,Humans ,Retroperitoneoscopic nephroureterectomy ,Retroperitoneal Space ,Risk factor ,Fisher's exact test ,Aged ,Retrospective Studies ,Urine cytology ,Upper urinary tract ,Carcinoma, Transitional Cell ,Bladder cancer ,medicine.diagnostic_test ,Ureteral Neoplasms ,business.industry ,Research ,Medical record ,Neoplasms, Second Primary ,General Medicine ,Middle Aged ,medicine.disease ,Diseases of the genitourinary system. Urology ,Kidney Neoplasms ,Exact test ,Pneumoretroperitoneum time ,Urinary Bladder Neoplasms ,Reproductive Medicine ,Concomitant ,Intravesical recurrence ,symbols ,Female ,Laparoscopy ,Urothelial carcinoma ,RC870-923 ,Neoplasm Recurrence, Local ,business - Abstract
Background One of the major concerns of patients with upper tract urothelial carcinoma (UTUC) treated with nephroureterectomy is intravesical recurrence (IVR). The purpose of the present study was to investigate the predictive risk factors for IVR after retroperitoneoscopic nephroureterectomy (RNU) for UTUC. Methods Clinicopathological and surgical information were collected from the medical records of 73 patients treated with RNU for non-metastatic UTUC, without a history of or concomitant bladder cancer. The association between IVR after RNU and clinicopathological and surgery-related factors, including preoperative urine cytology and pneumoretroperitoneum time, was analyzed using the Fisher exact test. Results During the median follow-up time of 39.1 months, 18 (24.7%) patients had subsequent IVR after RNU. The 1- and 3-year IVR-free survival rates were 85.9% and 76.5%, respectively. The Fisher exact test revealed that prolonged pneumoretroperitoneum time of ≥ 210 min was a risk factor for IVR in 1 year after RNU (p = 0.0358) and positive urine cytology was a risk factor for IVR in 3 years after RNU (p = 0.0352). Conclusions In UTUC, the occurrences of IVR in 1 and 3 years after RNU are highly probable when the pneumoretroperitoneum time is prolonged (≥ 210 min) and in patients with positive urine cytology, respectively. Strict follow-up after RNU is more probable recommended for these patients.
- Published
- 2021
- Full Text
- View/download PDF
18. Failure of Hem-o-lok clips used on a renal artery after laparoscopic renal surgery
- Author
-
Tsutomu Hamasaki, Masato Yanagi, Yuki Endo, Hiroyuki Shimizu, Jun Akatsuka, Ryoji Kimata, Yukihiro Kondo, Hayato Takeda, and Tatsuro Hayashi
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,education ,Pulsatile flow ,Kidney ,urologic and male genital diseases ,Nephrectomy ,General Biochemistry, Genetics and Molecular Biology ,Renal Artery ,Laparotomy ,medicine.artery ,medicine ,Humans ,cardiovascular diseases ,CLIPS ,Renal artery ,computer.programming_language ,business.industry ,Renal surgery ,General Medicine ,Middle Aged ,Surgical Instruments ,nervous system diseases ,Surgery ,surgical procedures, operative ,Hemorrhagic shock ,Cuff ,Laparoscopy ,Ligation ,business ,computer - Abstract
Hem-o-lok clips are commonly used for renal artery ligation in laparoscopic renal surgery. However, failure of the renal artery ligation clips is potentially fatal. A 61-year-old man underwent hand-assisted laparoscopic nephroureterectomy using a retroperitoneal approach for left ureteral carcinoma. One hour postoperatively, he was diagnosed with hemorrhagic shock. An immediate laparotomy revealed two closed, undamaged Hem-o-lok clips around the left renal artery. Pulsatile bleeding was observed, and the renal artery was immediately ligated with non-absorbable thread. We determined that the failure of the Hem-o-lok clips on the renal artery was caused by the lack of space between the two Hem-o-lok clips and the distal renal artery cuff beyond the distal clip. To prevent a potentially fatal failure of the renal artery ligation clips, one should maintain a sufficient space between the Hem-o-lok clips and an adequate distal renal artery cuff beyond the distal clip. J. Med. Invest. 68 : 393-395, August, 2021.
- Published
- 2021
- Full Text
- View/download PDF
19. The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis
- Author
-
Kazutoshi Fujita, Go Kimura, Toyonori Tsuzuki, Taigo Kato, Eri Banno, Akira Kazama, Ryo Yamashita, Yuto Matsushita, Daisuke Ishii, Tomoya Fukawa, Yuki Nakagawa, Tamaki Fukuyama, Fumikazu Sano, Yukihiro Kondo, and Hirotsugu Uemura
- Subjects
TIME (tumor immune microenvironment) ,synchronous ,metachronous ,mRCC (metastatic renal cell carcinoma) ,PD-L1 ,immunophenotype ,Cancer Research ,Oncology - Abstract
Biological or immunological differences in primary lesions between synchronous and metachronous metastatic renal cell carcinoma (mRCC) have been reported. However, the association between the tumor immune microenvironment (TIME) of primary lesions and time to metastasis remains unknown. We investigated the differences in the TIME of primary lesions based on time intervals to metastasis, mainly between the synchronous group (SG; metastasis within 3 months) and metachronous group (MG; metastasis after 3 months), and its association with clinicopathological parameters in patients with mRCC. Overall, 568 patients treated first-line with vascular endothelial growth factor receptor inhibitors comprised the analysis population (SG: N = 307 [54.0%]; MG: N = 261 [46.0%]). SG had a higher proportion of patients with poor prognostic pathological feature tumors: WHO/ISUP grade 4, necrosis, lymphovascular invasion, infiltrative growth pattern, and sarcomatoid differentiation. Regarding the TIME, more immunogenic features were seen in SG than MG, with a higher PD-L1 positivity and a lower proportion of the desert phenotype. This is the first study to examine the differences in the TIME of primary lesions in patients with mRCC based on the time intervals to metastasis. The TIME of primary lesions could affect the time to metastasis.
- Published
- 2022
- Full Text
- View/download PDF
20. Risk Factor Analysis of Intravesical Recurrence After Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma
- Author
-
Masato Yanagi, Tsutomu Hamasaki, JunJun Akatsuka, Yuki Endo, Hayato Takeda, and Yukihiro Kondo
- Abstract
Background: One of the major concerns of patients with upper tract urothelial carcinoma (UTUC) treated with nephroureterectomy is intravesical recurrence (IVR). The purpose of the present study was to investigate the predictive risk factors for IVR after laparoscopic nephroureterectomy (LNU) for UTUC.Methods: Clinicopathological and surgical information were collected from the medical records of 73 patients treated with LNU for non-metastatic UTUC, without a history of or concomitant bladder cancer. The association between IVR after LNU and clinicopathological and surgery-related factors, including preoperative urine cytology and pneumoperitoneum time, was analyzed using Cox proportional hazards regression models and the Kaplan–Meier method with log-rank test.Results: During the median follow-up time of 39.1 months, 18 (24.7%) patients had subsequent IVR after LNU. The 3- and 5-year IVR-free survival rates were 76.5% and 74.3%, respectively. In the multivariate Cox regression analysis, positive preoperative urine cytology (hazard ratio [HR]: 3.55; 95% confidence interval [CI]: 1.326–11.327; p=0.011) and prolonged pneumoperitoneum time of ≥ 210 min (HR: 3.40; 95% CI: 1.271–10.692; p=0.014) were independent prognostic factors for IVR-free survival. In patients with positive urine cytology, the Kaplan–Meier method with log-rank test revealed that the 3-year and 5-years IVR free survival rates were 46.3% and 39.7%, respectively, in patients with a prolonged pneumoperitoneum time of ≥ 210 min, which was significantly lower than that in their counterparts (76% and 76%, respectively, p=0.041).Conclusions: In UTUC patients with positive urine cytology, the occurrence of IVR is highly probable when the pneumoperitoneum time of LNU is prolonged (≥ 210 min). Strict follow-up after LNU is highly recommended for these patients.
- Published
- 2021
- Full Text
- View/download PDF
21. Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan
- Author
-
Yukihiro Kondo, Takeshi Yuasa, Shinya Yamamoto, Noboru Numao, Shotaro Yasuoka, Masahiro Ogawa, Junji Yonese, and Yoshinobu Komai
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Anemia ,Antineoplastic Agents ,Docetaxel ,urologic and male genital diseases ,Disease-Free Survival ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Japan ,Risk Factors ,Interquartile range ,Internal medicine ,medicine ,Humans ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Medical record ,Neoplasms, Second Primary ,Retrospective cohort study ,General Medicine ,Middle Aged ,Prostate-Specific Antigen ,medicine.disease ,Prostatic Neoplasms, Castration-Resistant ,Treatment Outcome ,Cabazitaxel ,030220 oncology & carcinogenesis ,Taxoids ,business ,medicine.drug - Abstract
BACKGROUND/AIM Cabazitaxel (CBZ) is approved for docetaxel-resistant castration-resistant prostate cancer (CRPC). This retrospective study aimed at assessing the efficacy and prognostic markers of cabazitaxel treatment in Japanese CRPC patients. PATIENTS AND METHODS The medical records of 44 consecutive Japanese patients with CRPC who started cabazitaxel at our Institution between January 2011 and February 2019 were reviewed and statistically analysed. RESULTS The median follow-up period after cabazitaxel initiation was 13.2 [interquartile range (IQR)=6.9-21.5] months. The objective response rate, median progression-free survival period, and median overall survival period (OS) were 45.5%, 4.3 months, and 20.7 months, respectively. On multivariate analysis, higher prostate-specific antigen (PSA; >100 ng/ml), lower haemoglobin (
- Published
- 2019
- Full Text
- View/download PDF
22. Induction of tumor-specific CD8+ cytotoxic T lymphocytes from naïve human T cells by using Mycobacterium-derived mycolic acid and lipoarabinomannan-stimulated dendritic cells
- Author
-
Masumi Shimizu, Eri Watanabe, Yasuyuki Negishi, Yukihiro Kondo, Yuji Tomita, and Hidemi Takahashi
- Subjects
Lipopolysaccharides ,Cancer Research ,Lipoarabinomannan ,Thrombomodulin ,CD3 ,Immunology ,chemical and pharmacologic phenomena ,Major histocompatibility complex ,DCs ,Mycobacterium ,CTLs ,03 medical and health sciences ,0302 clinical medicine ,Antigen ,Cell Line, Tumor ,Neoplasms ,Humans ,Immunology and Allergy ,Cytotoxic T cell ,BCG ,030304 developmental biology ,CD86 ,0303 health sciences ,Mycolic acid ,biology ,Chemistry ,hemic and immune systems ,Mycobacterium tuberculosis ,Dendritic Cells ,Interleukin-12 ,Mycobacterium bovis ,Cell biology ,CTL ,Mycolic Acids ,Oncology ,Antigens, Surface ,biology.protein ,Original Article ,CD8 ,CD80 ,T-Lymphocytes, Cytotoxic ,030215 immunology - Abstract
The main effectors in tumor control are the class I MHC molecule-restricted CD8+ cytotoxic T lymphocytes (CTLs). Tumor-specific CTL induction can be regulated by dendritic cells (DCs) expressing both tumor-derived epitopes and co-stimulatory molecules. Immunosuppressive tolerogenic DCs, having down-regulated co-stimulatory molecules, are seen within the tumor mass and can suppress tumor-specific CTL induction. The tolerogenic DCs expressing down-regulated XCR1+CD141+ appear to be induced by tumor-derived soluble factors or dexamethasone, while the immunogenic DCs usually express XCR1+CD141+ molecules with a cross-presentation function in humans. Thus, if tolerogenic DCs can be reactivated into immunogenic DCs with sufficient co-stimulatory molecules, tumor-specific CD8+ CTLs can be primed and activated in vivo. In the present study, we converted human tolerogenic CD141+ DCs with enhanced co-stimulatory molecule expression of CD40, CD80, and CD86 through stimulation with non-toxic mycobacterial lipids such as mycolic acid (MA) and lipoarabinomannan (LAM), which synergistically enhanced both co-stimulatory molecule expression and interleukin (IL)-12 secretion by XCR1+CD141+ DCs. Moreover, MA and LAM-stimulated DCs captured tumor antigens and presented tumor epitope(s) in association with class I MHCs and sufficient upregulated co-stimulatory molecules to prime naïve CD3+ T cells to become CD8+ tumor-specific CTLs. Repeat CD141+ DC stimulation with MA and LAM augmented the secretion of IL-12. These findings provide us a new method for altering the tumor environment by converting tolerogenic DCs to immunogenic DCs with MA and LAM from Mycobacterium tuberculosis.
- Published
- 2019
- Full Text
- View/download PDF
23. Initial Experience of Pembrolizumab Therapy in Japanese Patients With Metastatic Urothelial Cancer
- Author
-
Yukihiro Kondo, Takeshi Yuasa, Masahiro Ogawa, Shinya Yamamoto, Noboru Numao, Shotaro Yasuoka, Junji Yonese, Yoshinobu Komai, and Noriko Nishimura
- Subjects
Male ,Oncology ,Urologic Neoplasms ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Pilot Projects ,Pembrolizumab ,Antibodies, Monoclonal, Humanized ,Metastasis ,03 medical and health sciences ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Asian People ,Internal medicine ,Humans ,Medicine ,Urothelial cancer ,Potency ,Objective response ,Aged ,Aged, 80 and over ,Performance status ,business.industry ,Medical record ,General Medicine ,Middle Aged ,medicine.disease ,Survival Analysis ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,business - Abstract
Background/aim Pembrolizumab was approved as second-line treatment for patients with metastatic urothelial cancer (UC) in Japan. We performed a retrospective pilot study to assess the potency of pembrolizumab treatment in Japan. Patients and methods The medical records of 40 consecutive Japanese patients with metastatic UC who started pembrolizumab between January and October 2018 were reviewed and statistically analyzed to clarify the efficacy and safety of the drug. Results The objective response rate, median progression-free survival period, and median overall survival period were 20.6%, 4.1 months and 10.0 months, respectively. Multivariate analysis indicated the presence of liver metastasis, worse performance status (≥2), and higher C-reactive protein as factors predictive of shorter OS. Conclusion We demonstrated for the first time, a comparable efficacy and safety profile of pembrolizumab for Japanese patients with metastatic UC, as in the KEYNOTE-045 study. The results indicate the features of pembrolizumab therapy in the current Japanese clinical practice.
- Published
- 2019
- Full Text
- View/download PDF
24. Safety of Abiraterone Acetate Administration in Elderly Patients Receiving Peritoneal Dialysis with Castration-Resistant Prostate Cancer: Two Case Reports
- Author
-
Yuji Tomita, Ryoji Kimata, and Yukihiro Kondo
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Prednisolone ,medicine.medical_treatment ,Abiraterone Acetate ,Urology ,Administration, Oral ,Antineoplastic Agents ,Hypokalemia ,Castration resistant ,urologic and male genital diseases ,Peritoneal dialysis ,chemistry.chemical_compound ,Prostate cancer ,Antigen ,medicine ,Humans ,Castration ,Adverse effect ,Aged, 80 and over ,business.industry ,Abiraterone acetate ,General Medicine ,medicine.disease ,Prostatic Neoplasms, Castration-Resistant ,Treatment Outcome ,chemistry ,Potassium ,medicine.symptom ,business ,Peritoneal Dialysis ,medicine.drug - Abstract
We report two elderly patients receiving peritoneal dialysis with castration-resistant prostate cancer (CRPC). Herein, we show that the patients were safely treated using abiraterone acetate (750 mg/day orally once daily) and prednisolone (5 mg/day orally once daily). Although the prostate-specific antigen (PSA) level increased in both cases, there was no manifestation of disease progression (clinical and radiographic) for 22 months in case 1 and 8 months in case 2. In case 2, the only adverse event was hypokalemia, which was treated using potassium preparations.
- Published
- 2019
- Full Text
- View/download PDF
25. A CASE OF THROMBOSIS OF THE PAMPINIFORM PLEXUS TREATED WITH ANTICOAGULANT THERAPY
- Author
-
Jun Akatsuka, Shigehito Minaguchi, Yasutomo Suzuki, Shunichiro Nomura, Tsutomu Hamasaki, Yukihiro Kondo, and Go Kimura
- Subjects
Adult ,Male ,medicine.medical_specialty ,Urology ,Physical examination ,Asymptomatic ,Pampiniform plexus ,Scrotum ,medicine ,Humans ,Spermatic Cord ,medicine.diagnostic_test ,business.industry ,Anticoagulants ,Thrombosis ,Magnetic resonance imaging ,Heparin ,medicine.disease ,Magnetic Resonance Imaging ,Surgery ,medicine.anatomical_structure ,medicine.vein ,Anticoagulant therapy ,medicine.symptom ,Tomography, X-Ray Computed ,business ,medicine.drug - Abstract
We describe a patient with thrombosis of the pampiniform plexus cured using heparin. A 40-year-old man was referred to our hospital with pain in the left scrotum. A physical examination revealed a painful, 20-mm long, beaded mass in the upper left paratesticular region. Magnetic resonance imaging and ultrasonography revealed 10-mm long thrombosis in the left pampiniform plexus, so intravenous heparin was started. The patient recovered well and was discharged on oral anticoagulation therapy after five days of hospitalization. The patient was completely asymptomatic, and ultrasonographic findings of the left testicle were normal at six months after starting treatment. We found 19 patients with thrombosis of the pampiniform plexus including the present patient, in the English and Japanese literature to date. Here, we review these 19 patients and discuss their clinical features.
- Published
- 2019
- Full Text
- View/download PDF
26. Identification and characterization of nanoparticles secreted from the prostate cancer cell line PC-3
- Author
-
Syunya Noguchi, Takanobu Sakurai, Yukihiro Kondo, and Toshihiro Takizawa
- Subjects
Reproductive Medicine ,Immunology ,Obstetrics and Gynecology ,Immunology and Allergy - Published
- 2022
- Full Text
- View/download PDF
27. Long Noncoding RNA
- Author
-
Aya, Misawa, Yukihiro, Kondo, Hiroyuki, Takei, and Toshihiro, Takizawa
- Subjects
Homeodomain Proteins ,Male ,Osteoblasts ,Gene Expression Profiling ,Prostatic Neoplasms ,Bone Neoplasms ,HOXB13 ,prostate cancer ,Article ,HOXA11-AS ,Gene Expression Regulation, Neoplastic ,Cell Line, Tumor ,Humans ,metastasis ,RNA, Long Noncoding ,long noncoding RNA ,Transcriptome ,Chemokine CCL2 - Abstract
Long noncoding RNAs (lncRNAs) are emerging as critical regulators of gene expression, which play fundamental roles in cancer development. In this study, we found that homeobox A11 antisense RNA (HOXA11-AS), a highly expressed lncRNA in cell lines derived from prostate cancer bone metastases, promoted the cell invasion and proliferation of PC3 prostate cancer cells. Transcription factor homeobox B13 (HOXB13) was identified as an upstream regulator of HOXA11-AS. HOXA11-AS regulated bone metastasis-associated C-C motif chemokine ligand 2 (CCL2)/C-C chemokine receptor type 2 (CCR2) signaling in both PC3 prostate cancer cells and SaOS2 osteoblastic cells. The HOXB13/HOXA11-AS axis also regulated integrin subunits (ITGAV and ITGB1) specific to prostate cancer bone metastasis. HOXB13, in combination with HOXA11-AS, directly regulated the integrin-binding sialoprotein (IBSP) promoter. Furthermore, conditioned medium containing HOXA11-AS secreted from PC3 cells could induce the expression of CCL2 and IBSP in SaOS2 osteoblastic cells. These results suggest that prostate cancer HOXA11-AS and HOXB13 promote metastasis by regulation of CCL2/CCR2 cytokine and integrin signaling in autocrine and paracrine manners.
- Published
- 2020
28. Factors Associated with Prolonged Retroperitoneal Laparoscopic Radical Nephrectomy Performed by Non-expert Surgeons
- Author
-
Yanagi, Masato, Kimura, Go, Sekine, Tetsuro, Takeda, Hayato, Akatsuka, Jun, Endo, Yuki, Hayashi, Tatsuro, Hamasaki, Tsutomu, Kondo, Yukihiro, Masato, Yanagi, Go, Kimura, Tetsuro, Sekine, Hayato, Takeda, Jun, Akatsuka, Yuki, Endo, Tatsuro, Hayashi, Tsutomu, Hamasaki, and Yukihiro, Kondo
- Subjects
Laparoscopic surgery ,Male ,Risk ,medicine.medical_specialty ,Certification ,medicine.medical_treatment ,Operative Time ,Nephrectomy ,Body Mass Index ,Specimen Handling ,03 medical and health sciences ,0302 clinical medicine ,Renal cell carcinoma ,medicine ,Humans ,Retroperitoneal Space ,Carcinoma, Renal Cell ,Retroperitoneal approach ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Adrenalectomy ,Medical record ,General Medicine ,medicine.disease ,Kidney Neoplasms ,Surgery ,030220 oncology & carcinogenesis ,T-stage ,030211 gastroenterology & hepatology ,Laparoscopic radical nephrectomy ,Female ,Laparoscopy ,Clinical Competence ,business ,Body mass index - Abstract
Background While high body mass index (BMI) and visceral obesity are reportedly associated with a prolonged duration of laparoscopic radical nephrectomy (LRN) via the transperitoneal approach, factors that might prolong the retroperitoneal approach remain unknown. We therefore investigated factors associated with prolonged LRN using a retroperitoneal approach applied by non-expert surgeons. Methods We defined surgeons who were not certified to perform laparoscopic surgery by the Japanese Society of Endourology as non-experts. We retrospectively reviewed the medical records of 59 consecutive patients with renal cell carcinoma treated with LRN using the retroperitoneal approach by non-experts at our hospital between 2014 and 2019. Relationships between surgical duration and age, sex, body mass index, visceral fat area (VFA) and subcutaneous fat area (SFA), laterality and location of the tumor, length of major tumor axis (tumor length), clinical T stage, ipsilateral adrenalectomy and specimen weight were analyzed using Spearman rank correlation coefficients. Results The surgical duration positively correlated with ipsilateral adrenalectomy (rs = 0.3162, p = 0.0147) and specimen weight (rs = 0.3103, p = 0.0168), but not with BMI (rs = 0.2016, p = 0.1257) or VFA (rs = 0.0185, p = 0.8894). Conclusions Factors associated with prolonged LRN via the retroperitoneal approach implemented by non-expert surgeons are ipsilateral adrenalectomy and specimen weight.
- Published
- 2020
29. MP17-15 LIPID CELL VARIANT OF UROTHELIAL CARCINOMA - EVALUATION OF TUMOR AGGRESSIVENESS AND DEMONSTRATION OF LIPID COMPONENT
- Author
-
Mikio Shibasaki, Jyun Akatsuka, Yukihiro Kondo, Naoto Hodotsuka, Hayato Takeda, Ryo Amakawa, Tatsuro Hayashi, Yuki Endo, Hiroya Hasegawa, and Go Kimura
- Subjects
medicine.anatomical_structure ,business.industry ,Urology ,Cell ,Cancer research ,Medicine ,business ,Urothelial carcinoma - Abstract
INTRODUCTION AND OBJECTIVE:Lipid cell variant (LCV) of urothelial carcinoma (UC), which was first described by Mostofi et al in 1999, is a very rare variant of UC. Since then, only a limited number...
- Published
- 2020
- Full Text
- View/download PDF
30. MP76-11 THE DIAGNOSTIC AND PROGNOSTIC VALUE OF TUMOR MARKER DENSITIES IN MARKER POSITIVE TESTICULAR CANCER
- Author
-
Shuhei Nozaki, Shigehito Minaguchi, Mikio Shibasaki, Hayato Takeda, Hikaru Mikami, Ryo Amakawa, Go Kimura, Masato Yanagi, Yuki Endo, Yukihiro Kondo, Tatsuro Hayashi, Jun Akatsuka, Hiroya Hasegawa, and Naoto Hodotsuka
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Urology ,Internal medicine ,medicine ,business ,medicine.disease ,Value (mathematics) ,Testicular cancer ,Tumor marker - Published
- 2020
- Full Text
- View/download PDF
31. Expression of epithelial-Mesenchymal transition related markers in Plasmacytoid Urothelial carcinoma of the urinary bladder
- Author
-
Yasutomo Suzuki, Tsutomu Hamasaki, Yukihiro Kondo, Jun Akatsuka, Yuki Endo, Shunichiro Nomura, Akira Shimizu, and Go Kimura
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Epithelial-Mesenchymal Transition ,Urology ,Bladder ,030232 urology & nephrology ,Vimentin ,lcsh:RC870-923 ,03 medical and health sciences ,0302 clinical medicine ,Carcinoma ,medicine ,Biomarkers, Tumor ,Humans ,Epithelial–mesenchymal transition ,Stage (cooking) ,Aged ,Aged, 80 and over ,Carcinoma, Transitional Cell ,Urinary bladder ,biology ,business.industry ,Incidence (epidemiology) ,E-cadherin ,Histology ,General Medicine ,Middle Aged ,medicine.disease ,lcsh:Diseases of the genitourinary system. Urology ,medicine.anatomical_structure ,Reproductive Medicine ,Urinary Bladder Neoplasms ,Snail ,Tumor progression ,030220 oncology & carcinogenesis ,biology.protein ,Plasmacytoid ,Female ,Urothelial carcinoma ,business ,Research Article - Abstract
Background Plasmacytoid urothelial carcinoma (PUC) of the urinary bladder is a variant of urothelial carcinoma that carries a poor prognosis. The epithelial-mesenchymal transition (EMT) has been demonstrated to contribute to tumor progression. As the cause of the increased aggressiveness of PUC is unknown, we investigated PUC and EMT-related marker expression. Methods A total of 633 bladder carcinoma cases diagnosed from 2006 to 2015 at the Nippon Medical School Hospital were analyzed. Twelve patients were found to have plasmacytoid histology and diagnosed with PUC. Slides were evaluated for percentage of plasmacytoid variant, and stained for E-cadherin, N-cadherin, Vimentin, Fibronectin and Snail expression. Results The incidence of PUC was 1.9% (12/633). The median patient age at diagnosis was 71 years (range, 60–80 years) and the male-female ratio was 11:1. All but three patients had stage T2b or higher. The median overall survival was 10 months. In 10/12 cases, Snail and N-cadherin were positive. Vimentin was positive in 9/12 cases. Fibronectin was positive in 8/12 cases. While E-cadherin was negative in 10/12 cases. Nine cases showed > 10% plasmacytoid component. Eight of the nine patients (88.9%) with > 10% plasmacytoid component died. Conclusions The results indicate that PUC may induce EMT and may be associated with high invasion.
- Published
- 2020
32. [CASE REPORT: COMPLETE RESECTION OF RETROPERITONEAL CYSTIC LYMPHANGIOMA AND SURROUNDING ORGANS]
- Author
-
Kuniaki Tanabe, Hiroki Nakamori, Ryo Matsuoka, Yasutomo Suzuki, Hiroyoshi Kono, Kaoru Nemoto, Kojiro Morita, Masato Yanagi, Hiroya Hasegawa, and Yukihiro Kondo
- Subjects
Male ,Right flank ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Urology ,Computed tomography ,Malignancy ,medicine.disease ,Complete resection ,Treatment Outcome ,Lymphangioma ,medicine ,Vomiting ,Retroperitoneal cystic lymphangioma ,Humans ,Neoplasm Invasiveness ,Radiology ,Lymphangioma, Cystic ,Retroperitoneal Neoplasms ,medicine.symptom ,business ,Pathological ,Aged - Abstract
A 65-year-old man was admitted to our institution with vomiting and right flank pain. Computed tomography (CT) imaging showed a 21-cm retroperitoneal multilocular cystic tumor which had been identified four years previously. It had increased from 17 to 21 cm. The initial diagnosis was cystic lymphangioma because it was a clear cystic tumor without a boundary or a solid component in the first CT, but later CT revealed an unclear boundary with surrounding organs suggesting malignancy. We decided to resect the tumor because it was symptomatic and might be malignant. The tumor was then resected along with surrounding organs because invasion was suspected. Pathological findings indicated a diagnosis of cystic lymphangioma with chronic inflammation and confirmed complete resection of the tumor. The patient has remained free of recurrence at one year after surgery. This experience indicates that cystic lymphangioma should be completely resected to prevent recurrence.
- Published
- 2020
33. Prognostic impact of serum cytokeratin 19 fragments in patient with metastatic urothelial cancer treated with immune checkpoint inihibitors
- Author
-
Yuki Endo, Go Kimura, Jun Akatsuka, Hayato Takeda, Masato Yanagi, Hikaru Mikami, Shunsuke Ikuma, Yuka Toyama, and Yukihiro Kondo
- Subjects
Cancer Research ,Oncology - Abstract
555 Background: Recent clinical trials such as Keynote-045, EV-201 and Javelin bladder100 have provided new therapeutic agents for metastatic urothelial carcinoma (mUC). However, the only tool that can evaluate the therapeutic responses is a radiological criteria, Response Evaluation Criteria in Solid Tumors (RECIST) in mUC. In the clinical practice, biomarkers that can predict the efficacy and prognosis of various agents are essential to treat these patients, and the search for such biomarkers is urgently needed. We reported that Performance status ≥ 1, liver metastasis and elevated serum cytokeratin 19 fragments (sCYFRA) are the prognostic factors for first-line cytotoxic cheomotherapy (CTC) for mUC. In this study we evaluated pretreated clinical biomarkers including sCYFRA that can predict overall survival (OS) in patients with mUC treated with immune-checkpoint inhibitors (ICI). Methods: Thirty four patients with mUC received pembrolizuab (PB) from February 2018 to July 2020 at our institution. We retrospectively collected performance status, metastasis site, blood neutrophil-lymphocyte ratio (NLR), hemoglobin (Hb), and serum levels of lactose dehydrogenase (LD), alkaline phosphatase (ALP), C-reacted protein (CRP), total protein, albumin, corrected calcium (Ca), carbohydrate antigen19-9, sCYFRA before PB was administered. OS rate were analyzed by Kaplan-Meier curves and log-rank test. Multivariate analysis was carried out using the Cox hazards model. Objective Response rate (ORR) was evaluated based on RECIST (version 1.1). Results: Of 34 patients (Pts), with median age of 73(31-86), during the median follow-up period of 25 (7-126) months, 21patients (65%) had died. Median OS was 9.2 months (0.2-33.4), A 1-year OS rate was 33%. ORR was 33% and 9 Pts was SD (27%) and 14 pts (40%) was progressive disease. On univariate analysis, bone metastasis (p=0.028), LD (p=0.003), ALP (p=0.001), Ca (p=0.003) and sCYFRA (p=0.001) were the significant prognostic factor for OS. On multivariate analysis, ALP (HR9.2, 95%CI [2.89-135.9], p=0.002), Ca (HR7.3, (95%CI [2.36-22.49], p=0.001), sCYFRA (HR 5.0, 95%CI [1.63-15.55], p=0.005) were the significant prognostic factor for OS. Based on these 3 factors we divided pts into three groups, good risk (G1,0 factor), intermediate risk (G2, 1 factor) and poor risk (G3, 2-3 factors)3. There was a significant difference between the three groups for OS on K-M curve (G1 vs G2, p=0.001, G2vs G3, p=0.009). Conclusions: sCYFRA, ALP and Ca were the independent prognostic factors for OS in patients with mUC treated with ICI. sCYFRA was the independent prognostic factor for OS in the 1st line CTC and 2nd line ICI and it can be a prognostic factor though those therapies.
- Published
- 2022
- Full Text
- View/download PDF
34. Vesical Imaging-Reporting and Data System (VI-RADS)
- Author
-
Shunsuke Ikuma, Go Kimura, Hikaru Mikami, Masato Yanagi, Yuki Endo, Hayato Takeda, Jun Akatsuka, Yuka Toyama, and Yukihiro Kondo
- Subjects
Cancer Research ,Oncology - Abstract
453 Background: The VI-RADS has been widely used as diagnostic criteria for MRI to predict muscle-invasive of bladder cancer (MIBC). The aim of this study is to evaluate the diagnostic performance of VI-RADS in our hospital and the clinicopathological features of true positive (TP), false positive (FP), true negative (TN), and false negative (FN) cases to identify possible factors for misdiagnosis. Methods: Of the 286 patients who underwent TURBT at our hospital from January 2019 to October 2020, we selected 129 consecutive cases who had performed preoperative enhanced mpMRI and diagnosed as urothelial carcinoma pathologically. We defined VI-RADS score ≥4 as positive for MIBC. The clinicopathological features of TP, FP, TN, and FN groups were retrospectively analyzed and compared. Chi-square test and Mann–Whitney U test were used for the test between the two groups. Results: VI-RADS score in MIBC cases were 2 cases for ≤3 and 22 for ≥4, and in non-MIBC cases 91 cases for ≤3 and 14 for ≥4. The diagnostic performance of VI-RADS for MIBC was 92% for sensitivity, 87% for specificity, 61% for positive predictive value, 98% for negative predictive value, 88% for accuracy and the area under the curve (AUC) was 0.89. There were no statistical differences of age and %male cases between TP (22 cases), FP (14), TN (91) and FN (2) groups. Pathological features of the (TP, FP, TN, FN) groups were shown (table). TP had significantly larger tumor size than the other three groups, and higher %G3, %tumor necrosis and %variant+ than FP and TN. FP group had significantly larger tumor size than the TN. Conclusions: VI-RADS showed high diagnostic performance in predicting MIBC. Our study showed that larger tumor size was a significant factor for overestimation, suggesting the need for improved accuracy in cases with large tumor size.[Table: see text]
- Published
- 2022
- Full Text
- View/download PDF
35. POSTERIOR PERIURETHRAL ABSCESSES DUE TO NEISSERIA GONORRHOEAE POSED DIAGNOSTIC DIFFICULTIES
- Author
-
Yukihiro Kondo, Yasutomo Suzuki, Narumi Tsuboi, Tsuyoshi Miura, Kaoru Nemoto, Tadaaki Minowa, and Masato Yanagi
- Subjects
medicine.medical_specialty ,Cystostomy ,business.industry ,Urology ,bacterial infections and mycoses ,medicine.disease ,medicine.disease_cause ,Surgery ,medicine.anatomical_structure ,Prostate ,medicine ,Neisseria gonorrhoeae ,Ceftriaxone ,Periurethral abscess ,Ct findings ,Abscess ,business ,medicine.drug - Abstract
Posterior periurethral abscesses due to Neisseria gonorrhoeae are rare and thus difficult to diagnose and treat. We diagnosed this type of abscess using MRI and treated it conservatively.A 27-year-old man presented with perineal discomfort that had persisted for 1 week. Physical and CT findings indicated a prostate abscess, but MRI after admission revealed a multilocular mass in the posterior periurethra and polymerase chain reaction was positive for Neisseria gonorrhoeae. The posterior periurethral abscess was treated with Ceftriaxone and drainage via a cystostomy. This strategy improved the inflammation and CT confirmed the disappearance of the abscess from start of therapy in 43 days.
- Published
- 2018
- Full Text
- View/download PDF
36. A Case of Primary Malignant Lymphoma of the Prostate Gland Presenting as Right Lower Back Pain and Dysuria
- Author
-
Kotaro Obayashi, Yukihiro Kondo, Satoko Nakayama, Keita Shibayama, Keichi Moriya, Tatsuro Hayashi, Yasushi Inoue, Takao Shindo, Tsutomu Hamasaki, Keigo Takahashi, Yuki Endo, Shotaro Yasuoka, Jun Akatsuka, Shigeki Iigaya, Yuka Toyama, Koiti Inokuchi, Go Kimura, and Ryo Matsuoka
- Subjects
Male ,medicine.medical_specialty ,Lymphoma ,Obturator Lymph Node ,030232 urology & nephrology ,03 medical and health sciences ,0302 clinical medicine ,Prostate ,Dysuria ,Positron Emission Tomography Computed Tomography ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers, Tumor ,medicine ,Back pain ,Humans ,Hydronephrosis ,Aged ,Digital Rectal Examination ,medicine.diagnostic_test ,business.industry ,Prostatic Neoplasms ,Combination chemotherapy ,General Medicine ,Rectal examination ,Prostate-Specific Antigen ,medicine.disease ,Treatment Outcome ,medicine.anatomical_structure ,Back Pain ,030220 oncology & carcinogenesis ,Stents ,Lymphoma, Large B-Cell, Diffuse ,Radiology ,medicine.symptom ,Tomography, X-Ray Computed ,business - Abstract
A 73-year-old man presented with right lower back pain and dysuria. Right hydronephrosis and a large pelvic large mass were seen on computed tomography (CT). Although his prostate-specific antigen (PSA) was 0.5 ng/mL, an irregularly enlarged, stony, hard prostate was palpable on digital rectal examination. A prostate tumor was suspected, and a transrectal prostate biopsy and right transurethral ureteral stent placement were performed. Histological and immunohistochemical studies revealed diffuse large B-cell lymphoma. Positron emission tomography-computed tomography showed abnormal uptake in the stomach, cecum, right obturator lymph nodes, para-aortic lymph nodes, and dorsal left kidney. No abnormal findings were seen on bone marrow histology. Clinical stage IVA was confirmed according to Ann Arbor criteria. The patient achieved a complete response after 8 cycles of combination chemotherapy with rituximab, pirarubicin, cyclophosphamide, vincristine, and prednisolone.
- Published
- 2018
- Full Text
- View/download PDF
37. Early Transcatheter Arterial Embolization for the American Association for the Surgery of Trauma Grade 4 Blunt Renal Trauma in Two Institutions
- Author
-
Satoru Murata, Yasutomo Suzuki, Taiji Nishimura, Tsutomu Hamasaki, Yukihiro Kondo, Kimiyoshi Mizunuma, Masato Yanagi, Hiroyuki Yokota, and Masatoku Arai
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,030232 urology & nephrology ,Kidney ,Wounds, Nonpenetrating ,Severity of Illness Index ,Treatment failure ,Young Adult ,03 medical and health sciences ,Renal Artery ,0302 clinical medicine ,Blunt ,Japan ,Renal injury ,Cause of Death ,Catheterization, Peripheral ,medicine ,Humans ,Treatment Failure ,Embolization ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Arterial Embolization ,Medical record ,Interventional radiology ,General Medicine ,Middle Aged ,Embolization, Therapeutic ,Surgery ,Treatment Outcome ,030220 oncology & carcinogenesis ,Concomitant ,Female ,business - Abstract
OBJECTIVES To evaluate the efficacy of early transcatheter arterial embolization for hemodynamically stable patients with The American Association for the Surgery of Trauma (AAST) grade 4 blunt renal trauma. MATERIALS AND METHODS The medical records of consecutive patients with grade 4 blunt renal trauma who were transported to our two critical care centers in Japan and treated with early transcatheter arterial embolization (TAE) between 2001 and 2013 were retrospectively reviewed. Treatment failure was defined as the need for further surgical intervention or re-embolization after initial embolization. We divided these cases into two groups, a group who survived and a group who died, investigating the factors that led to death. RESULTS Seventeen patients underwent early TAE, with an average time between presentation and embolization for renal trauma of 125 minutes (66-214 minutes). There was no case of treatment failure. Three of the patients died, but none solely because of renal injury. Significant factors associated with patient death were the number of concomitant injured organs (p=0.04), the presence of pelvic fractures (p
- Published
- 2018
- Full Text
- View/download PDF
38. Current work environments: What problems are being faced by Japanese urologists?
- Author
-
Kaoru Nemoto, Yasutomo Suzuki, and Yukihiro Kondo
- Subjects
Cross-Cultural Comparison ,Urologists ,Urology ,Population Dynamics ,Population ,030232 urology & nephrology ,Job Satisfaction ,03 medical and health sciences ,0302 clinical medicine ,Japan ,Humans ,Medicine ,Health Workforce ,Workplace ,education ,Health Services Needs and Demand ,Medical education ,education.field_of_study ,business.industry ,United States ,Work environment ,Geographic distribution ,Work (electrical) ,030220 oncology & carcinogenesis ,business ,Computer technology - Abstract
Computer technology has contributed to innovative progress in industrial infrastructures and has had a major influence on various work environments. Evaluations of work environments are routinely carried out in Western countries, but historically there has been resistance to such evaluations in Japan. In this mini-review, we discuss the current work environments of urologists in Japan. The number of urologists has increased each year, and the population density of urologists was 5.4 (per 100 000 people) in 2014. The average age of urologists in Japan was 48.9 years, and the percentage of female urologists was just 5.3%. Additionally, the geographic distribution of urologists was uneven in Japan. From projections based on population dynamics, the need for more urologists in the near future will probably increase. Because medical environments vary depending on the country, it is necessary to understand current work environments in greater detail initially. Furthermore, we should determine original measures for the establishment of satisfactory urological work environments in Japan.
- Published
- 2018
- Full Text
- View/download PDF
39. Clinical Experience of Power Doppler Ultrasonography for the Differential Diagnosis of Hemorrhagic Cystitis in Elderly Patients
- Author
-
Susumu Kurita, Yukihiro Kondo, Tetsuo Nozaki, Go Kimura, Yasuyuki Morikawa, Chorsu Lee, Taiji Nishimura, Teruhide Watanabe, and Hiroyuki Abe
- Subjects
Power doppler ,medicine.medical_specialty ,business.industry ,medicine ,General Earth and Planetary Sciences ,Radiology ,Differential diagnosis ,Ultrasonography ,medicine.disease ,business ,General Environmental Science ,Hemorrhagic cystitis - Published
- 2018
- Full Text
- View/download PDF
40. A Case of Bilateral Simple Testicular Cysts
- Author
-
Yasuyuki Morikawa, Teruhide Watanabe, Yukihiro Kondo, Taiji Nishimura, Yoshio Ichinose, Susumu Kurita, and Chorsu Lee
- Subjects
medicine.medical_specialty ,Testicular Cyst ,business.industry ,medicine ,Radiology ,business ,Simple (philosophy) - Published
- 2018
- Full Text
- View/download PDF
41. Spontaneous Disappearance of Renal Cyst: A Case Report
- Author
-
Chorsu Lee, Susumu Kurita, Yoshikatu Tanahashi, Yasuyuki Morikawa, Taiji Nishimura, Yukihiro Kondo, Teruhide Watanabe, and Yoshio Ichinose
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,Spontaneous disappearance ,medicine ,Cyst ,business ,medicine.disease - Published
- 2018
- Full Text
- View/download PDF
42. Role of prostacyclin synthase in carcinogenesis
- Author
-
Chieko Yokoyama, Yuka Sasaki, Shuntaro Hara, Tsubasa Ochiai, Yukihiro Kondo, and Masaya Takamura
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Carcinogenesis ,Physiology ,Prostaglandin ,Peroxisome proliferator-activated receptor ,Prostacyclin ,medicine.disease_cause ,Biochemistry ,Gene Expression Regulation, Enzymologic ,Prostacyclin synthase ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Cytochrome P-450 Enzyme System ,Biosynthesis ,Neoplasms ,Internal medicine ,medicine ,Animals ,Humans ,Pharmacology ,chemistry.chemical_classification ,biology ,ATP synthase ,Cell Biology ,Intramolecular Oxidoreductases ,030104 developmental biology ,Enzyme ,Endocrinology ,chemistry ,030220 oncology & carcinogenesis ,biology.protein ,Cancer research ,lipids (amino acids, peptides, and proteins) ,Gene Deletion ,medicine.drug - Abstract
Prostacyclin (PGI2) synthase (PGIS) and microsomal prostaglandin (PG) E synthase-1 (PGES-1) functionally couple with inducible cyclooxygenase-2 (COX-2) as their upstream enzymes to produce PGI2 and PGE2, respectively. Non-steroidal anti-inflammatory drugs exert their pharmacological effects including antitumor effects by the inhibition of COX-2 and thereby suppress this PG biosynthesis. PGIS is abundantly expressed in vascular endothelial and smooth muscle cells and was shown to be critical for the regulation of platelet aggregation and vascular tone. In addition to its role in vascular regulation, PGIS was shown to be frequently down-regulated in several types of cancers, and the involvement of PGIS in carcinogenesis has been suggested. In this review, we summarize the current understanding of the roles of PGIS and PGIS-derived PGI2 in carcinogenesis.
- Published
- 2017
- Full Text
- View/download PDF
43. A CASE OF IgG4-RELATED DISEASE WITH THICKENING OF THE RENAL PELVIS AT LEFT RENAL HILUM DIAGNOSED BY OBTURATOR LYMPH NODE DISSECTION
- Author
-
Hideaki Ishii, Yasutomo Suzuki, Ryo Amakawa, Jun Akatsuka, Yukihiro Kondo, Tsutomu Hamasaki, and Go Kimura
- Subjects
medicine.medical_specialty ,Kidney ,integumentary system ,medicine.diagnostic_test ,business.industry ,Urology ,Obturator Lymph Node ,fungi ,medicine.disease ,medicine.anatomical_structure ,Lymphoplasmacytic Infiltrate ,parasitic diseases ,Biopsy ,Medicine ,IgG4-related disease ,Radiology ,skin and connective tissue diseases ,business ,Renal pelvis ,Kidney disease ,Urine cytology - Abstract
IgG4-related kidney disease (IgG4-RKD) is a comprehensive term for renal lesions associated with IgG4-related disease (IgG4-RD), which is a recently recognized clinical entity characterized by a dense lymphoplasmacytic infiltrate rich in IgG4+ plasma cells with fibrosis affecting several organs. A 70-year-old woman was referred to our hospital for an abnormality at the left renal hilum detected by CT scan. Urinalysis was negative, urine cytology was rated as Class IIIa, and contrast-enhanced CT revealed left renal pelvic wall thickening without an irregular lumen and swelling of bilateral obturator lymph nodes. Ureterorenoscopy and biopsy were performed, and results showed no evidence of malignancy. Then, laparoscopic pelvic lymphadenectomy was performed. Plasma cells were the predominant infiltrating inflammatory cells; immunostaining showed marked infiltration of IgG4+ plasma cells with >10 IgG4+ plasma cells per high-power field, and the IgG4+/IgG+ cell ratio was over 40%. Serum IgG4 was extremely high. We made a final diagnosis of possible IgG4-related disease according to Comprehensive diagnostic Criteria for IgG4-related disease 2011. We report a long-term (40-month) follow-up case of IgG4-related kidney disease without therapy because there are no symptoms.
- Published
- 2017
- Full Text
- View/download PDF
44. Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project
- Author
-
Shigekazu Ukawa, Koshi Nakamura, Emiko Okada, Makoto Hirata, Akiko Nagai, Zentaro Yamagata, Kaori Muto, Koichi Matsuda, Toshiharu Ninomiya, Yutaka Kiyohara, Yoichiro Kamatani, Michiaki Kubo, Yusuke Nakamura, Akiko Tamakoshi, Ichiro Miura, Katsuhiko Takatama, Yoshiyuki Nabeshima, Kazuo Misumi, Shiro Minami, Yukihiro Kondo, Go Kimura, Shigeo Horie, Shinichi Ohba, Shigaku Ikeda, Satoshi Asai, Mitsuhiko Moriyama, Yasuo Takahashi, Tomoaki Fujioka, Wataru Obara, Seijiro Mori, Hideki Ito, Satoshi Nagayama, Yoshio Miki, Akihide Masumoto, Akira Yamada, Yasuko Nishizawa, Ken Kodama, Keisei Okamoto, Susumu Kageyama, Yukihiro Koretsune, Yuko Nishigaki, and Tsutomu Yoshida
- Subjects
Adult ,Male ,Oncology ,BioBank Japan project ,medicine.medical_specialty ,Survival ,Epidemiology ,Disease ,Adenocarcinoma ,Management of prostate cancer ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Japan ,Risk Factors ,Cause of Death ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Tumor biomarker ,030212 general & internal medicine ,Family history ,Life Style ,Aged ,Biological Specimen Banks ,Neoplasm Staging ,Aged, 80 and over ,Gynecology ,lcsh:R5-920 ,Relative survival ,business.industry ,Prostatic Neoplasms ,General Medicine ,Middle Aged ,Prostate-Specific Antigen ,Lifestyle ,medicine.disease ,Omics ,Survival Rate ,030220 oncology & carcinogenesis ,Cohort ,Original Article ,lcsh:Medicine (General) ,business ,Follow-Up Studies - Abstract
Background Prostate cancer is the sixth leading cause of cancer-related deaths in Japan. We aimed to elucidate the clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan (BBJ) project. Methods Four thousand, seven hundred and ninety-three patients diagnosed with prostate cancer in the BBJ project were included. Clinical and histopathological data, including causes of death, were analyzed. Relative survival (RS) rates of prostate cancer were calculated. Results Four thousand, one hundred and seventy-one prostate cancer patients with available histological data had adenocarcinoma. The mean age of the patients was 72.5 years. The proportion of patients who were non-smokers, non-drinkers, had a normal body mass index, did not exercise, had a normal prostate-specific antigen level, and had a family history of prostate cancer were 30.7%, 28.0%, 66.6%, 58.1%, 67.6%, and 6.5%, respectively. The proportion of patients with Stage II, III, and IV disease were 24.4%, 7.3%, and 4.4%, respectively. After limiting to patients with a time from the initial diagnosis of prostate cancer to entry into the study cohort of ≤90 days (n = 869), the 5- and 10-year RS rates were 96.3% and 100.5%, respectively, although we were unable to consider management strategies due to a plenty of data missing. Conclusions We provide an overview of patients with prostate cancer in the BBJ project. Our findings, coupled with those from various high throughput “omics” technologies, will contribute to the implementation of prevention interventions and medical management of prostate cancer patients., Highlights • Prostate cancer represents the second leading cause of cancer incidence worldwide. • We aimed to provide an overview of patients with prostate cancer. • Based on prostate cancer histology, 99.3% had adenocarcinoma. • The 5- and 10-year relative survival rates were 96.3% and 100.5%. • Future studies will help develop preventive programs for prostate cancer.
- Published
- 2017
- Full Text
- View/download PDF
45. A Case of Sigmoid-Vesical Fistula Interposed by Abscess between the Sigmoid Colon and the Urinary Bladder
- Author
-
Chorsu Lee, Masaya Takahashi, Toshihiro Nakamoto, Yukihiro Kondo, Susumu Kurita, Keigo Takahashi, Maki Nunomura, Yasuyuki Morikawa, Teruhide Watanabe, Taiji Nishimura, and Yoshio Ichinose
- Subjects
medicine.medical_specialty ,Urinary bladder ,medicine.anatomical_structure ,business.industry ,Fistula ,medicine ,Sigmoid colon ,Sigmoid function ,medicine.disease ,Abscess ,business ,Surgery - Published
- 2017
- Full Text
- View/download PDF
46. A Case of Renal Cell Carcinoma Metastasis to the Penis
- Author
-
Sayuri Takahashi, Taiji Nishimura, Yukihiro Kondo, Susumu Kurita, Maki Nunomura, Takafumi Miura, Chorus Lee, and Go Kimura
- Subjects
Pathology ,medicine.medical_specialty ,medicine.anatomical_structure ,business.industry ,Renal cell carcinoma ,Medicine ,business ,medicine.disease ,Penis ,Metastasis - Published
- 2017
- Full Text
- View/download PDF
47. Treatment Results of Transurethral Resection of the Prostate by Non-Japanese Board-Certified Urologists for Benign Prostate Hyperplasia: Analysis by Resection Volume
- Author
-
Yasutomo Suzuki, Kuniaki Tanabe, Yuka Toyama, Yukihiro Kondo, Satoko Nakayama, Shunichiro Nomura, and Tadaaki Minowa
- Subjects
Male ,medicine.medical_specialty ,Certification ,Urology ,medicine.medical_treatment ,Prostatic Hyperplasia ,030232 urology & nephrology ,Treatment results ,urologic and male genital diseases ,Resection ,03 medical and health sciences ,0302 clinical medicine ,Prostate ,Physicians ,Specialty Boards ,Humans ,Medicine ,Aged ,Transurethral resection of the prostate ,Aged, 80 and over ,business.industry ,Gold standard ,Transurethral Resection of Prostate ,General Medicine ,Middle Aged ,Hyperplasia ,medicine.disease ,Treatment Outcome ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,International Prostate Symptom Score ,business ,Benign prostate - Abstract
Introduction Transurethral resection of the prostate (TURP) is the gold standard for surgical treatment of benign prostatic hyperplasia (BPH), but it has complications such as bleeding and transurethral resection syndrome. The treatment results of TURP performed by non-Japanese board-certified urologists were examined, and the results were analyzed according to the resection volume to determine how much resection volume was suitable for non-Japanese board-certified urologists. Materials and methods A total of 72 cases that underwent TURP for BPH at our hospital were examined. The patients were divided into three groups by resection volume ( 30 g). The operators were five non-Japanese board-certified urologists. Various clinical factors were examined among the three groups before and after TURP. Results The average operation time and resection volume were significantly different among the groups. There were more transfused cases with greater resection volume. The changes from before to after TURP in the International Prostate Symptom Score, total prostate volume, and maximum flow rate were significantly different among the three groups, but the rates of these changes were not. Conclusions In this study, TURP performed by non-Japanese board-certified urologists was relatively safe and achieved sufficient efficacy. Cases with resection volume less than 20 g appear the most appropriate for non-Japanese board-certified urologists.
- Published
- 2017
- Full Text
- View/download PDF
48. Emphysematous Pyelonephritis: Study of the Indication and the Timing of Percutaneous Drainage
- Author
-
Teruhide Watanabe, Yukihiro Kondo, Yoshio Ichinose, Yasuyuki Morikawa, Chorsu Lee, Taiji Nishimura, Susumu Kurita, and Go Kimura
- Subjects
medicine.medical_specialty ,Percutaneous ,business.industry ,Emphysematous pyelonephritis ,medicine ,Drainage ,business ,Surgery - Published
- 2017
- Full Text
- View/download PDF
49. Atypical pemphigus developed in a patient with urothelial carcinoma treated with nivolumab
- Author
-
Hidehisa Saeki, Toshihiko Hoashi, Yoko Funasaka, Yuki Endo, Norito Ishii, Yukihiro Kondo, Takashi Hashimoto, Michiko Ito, and Go Kimura
- Subjects
medicine.medical_specialty ,Chemotherapy ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Dermatology ,General Medicine ,medicine.disease ,Radiation therapy ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Pemphigus ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Biopsy ,medicine ,Carcinoma ,Nivolumab ,Skin pathology ,business ,Urothelial carcinoma - Published
- 2018
- Full Text
- View/download PDF
50. Automated acquisition of explainable knowledge from unannotated histopathology images
- Author
-
Yoichiro Yamamoto, Hiromu Morikawa, Taishi Takahara, Ichiro Maeda, Shin-ichi Tsuchiya, Hiroyuki Kanno, Takuji Tsuyuki, Akira Shimizu, Go Kimura, Ryuto Nakazawa, Jun Akatsuka, Yasushi Numata, Kotaro Tsutsumi, Manabu Fukumoto, Naonori Ueda, Masao Ueki, Yukihiro Kondo, Toyonori Tsuzuki, and Gen Tamiya
- Subjects
Male ,0301 basic medicine ,Computer science ,Image Processing ,Prognostic prediction ,General Physics and Astronomy ,Automation ,Computer-Assisted ,0302 clinical medicine ,Image Processing, Computer-Assisted ,Pathology ,lcsh:Science ,Cancer ,screening and diagnosis ,Multidisciplinary ,Contextual image classification ,Detection ,Knowledge ,Local ,030220 oncology & carcinogenesis ,Algorithms ,Data compression ,Urologic Diseases ,Science ,Bioengineering ,Image processing ,Article ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Artificial Intelligence ,Robustness (computer science) ,Humans ,business.industry ,Deep learning ,External validation ,Prostatic Neoplasms ,Pattern recognition ,General Chemistry ,Translational research ,Data Compression ,4.1 Discovery and preclinical testing of markers and technologies ,Neoplasm Recurrence ,030104 developmental biology ,ROC Curve ,Cancer imaging ,lcsh:Q ,Artificial intelligence ,Neoplasm Recurrence, Local ,business - Abstract
Deep learning algorithms have been successfully used in medical image classification. In the next stage, the technology of acquiring explainable knowledge from medical images is highly desired. Here we show that deep learning algorithm enables automated acquisition of explainable features from diagnostic annotation-free histopathology images. We compare the prediction accuracy of prostate cancer recurrence using our algorithm-generated features with that of diagnosis by expert pathologists using established criteria on 13,188 whole-mount pathology images consisting of over 86 billion image patches. Our method not only reveals findings established by humans but also features that have not been recognized, showing higher accuracy than human in prognostic prediction. Combining both our algorithm-generated features and human-established criteria predicts the recurrence more accurately than using either method alone. We confirm robustness of our method using external validation datasets including 2276 pathology images. This study opens up fields of machine learning analysis for discovering uncharted knowledge., Technologies for acquiring explainable features from medical images need further development. Here, the authors report a deep learning based automated acquisition of explainable features from pathology images, and show a higher accuracy of their method as compared to pathologist based diagnosis of prostate cancer recurrence.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.